Zytiga (abiraterone acetate), used in combination with the steroid prednisone, has been approved for treatment of advanced prostate cancer, the U.S. Food and Drug Administration said in a press release.
The growth of cancerous prostate tumors is fed by the male hormone testosterone, and the new combination drug blocks a protein that plays a key role in the body of testosterone production, the Agency said.
Zytiga has been evaluated in clinical studies involving some 1,195 men advanced with tumor prostate cancer continued to grow despite chemotherapy. The men who received the combination Zytiga/prednisone lived an average of 14.8 months, compared to 10.9 months men who took a placebo, the FDA said.
The adverse effects common to the combination of drugs included joint discomfort, low blood potassium, retention, muscle discomfort, puffs of heat, diarrhea, urinary tract infections, cough, high blood pressure, heart rate, increased urination anomalies frequentstomach aches and upper respiratory tract infections.
Zytiga is produced by Centocor Ortho Biotech, based in Horsham, PA.
No comments:
Post a Comment